CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis
| Autor: | Ali Raza, Aiysha Abid, Abdul Rafay Khan, Sadaf Firasat |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Graft Rejection
0301 basic medicine medicine.medical_specialty medicine.medical_treatment Single-nucleotide polymorphism Polymorphism Single Nucleotide 030226 pharmacology & pharmacy Gastroenterology Tacrolimus 03 medical and health sciences 0302 clinical medicine Internal medicine Genotype Genetics medicine Cytochrome P-450 CYP3A Humans Trough Concentration CYP3A5 Kidney transplantation Pharmacology Dose-Response Relationship Drug business.industry medicine.disease Kidney Transplantation surgical procedures operative 030104 developmental biology Immunosuppressive drug Meta-analysis Molecular Medicine business Immunosuppressive Agents |
| Zdroj: | The Pharmacogenomics Journal. 20:553-562 |
| ISSN: | 1473-1150 1470-269X |
| Popis: | Tacrolimus is an immunosuppressive drug widely used in kidney transplantation. Cytochrome P450 3A5 (CYP3A5) protein is involved in tacrolimus metabolism. Single nucleotide polymorphism in the CYP3A5 gene (6986A>G) results in alteration in metabolic activity of CYP3A5 protein which eventually affects the tacrolimus concentration. Patients with CYP3A5 expresser genotypes (A/A *1/*1 and A/G *1/*3) metabolize tacrolimus more rapidly than CYP3A5 nonexpressers (G/G *3/*3). We performed meta-analysis to estimate the effect of CYP3A5 polymorphism on the trough concentration–dose ratio (Co/D) and risk of renal allograft rejection with similar post-transplant periods and Asian vs. European populations. Our results showed that the tacrolimus Co/D ratio is significantly lower in CYP3A5 expresser group as compared with nonexpresser in Asian as well as in European populations at any post-transplant period (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink